Morphological Analysis of CDC2 and Glycogen Synthase Kinase 3β Phosphorylation as Markers of G2 → M Transition in Glioma

Table 2

(a) CDC2 Expression Profile in GBM, astrocytoma, and oligodendroglioma. Number of cases (𝑛) that showed upregulated, downregulated, and intermediate expression measures of CDC2 are illustrated. Log-ranked 𝑃-values of direct comparisons between the groups are shown. Up = upregulated, down = downregulated, int = intermediate expression, 𝑃-value = log ranked 𝑃-value. (b) CDC2 copy numbers in GBM, astrocytoma, and oligodendroglioma. Number of cases (𝑛) that showed amplified or deleted CDC2 are illustrated. >2x = more than or equal to two copies, <2x = less than or equal to two copies. Increased CDC2 copy number is associated with increased survival in GBM and astrocytoma, but not oligodendroglioma.

(a)

Statistic	GBM,WHO IV	Astrocytoma,WHO II-III	OligodendrogliomaWHO II-III
Upregulated expression (𝑛)	163	83	41
Downregulated expression (𝑛)	2	4	2
Intermediate expression (𝑛)	16	18	7
Up versus down 𝑃-value	.78	.72	.16
Up versus Int 𝑃-value	.77	.23	.99
Down versus Int 𝑃-value	.70	.39	.17
Up versus other 𝑃-value	.86	.34	.52
Down versus other 𝑃-value	.78	.64	.16
Int versus other 𝑃-value	.76	.22	.89

(b)

Tumor	Number deleted (<2𝑥)	Number amplified (>2𝑥)	Log-rank 𝑃-value
GBM, WHO IV	160	26	.029
Astrocytoma, WHO II-III	75	27	.029
Oligodendroglioma, WHO II-III	33	25	.86